Prüftechnik ShaftAlign Touch Laser Alignment System Enables Technicians to Quickly and Precisely Align the Majority of Standard Machines
16.9.2020 13:00:00 EEST | Business Wire | Press release
Prüftechnik, a division of Fluke Reliability, introduces the ShaftAlign Touch laser alignment system, a new digital solution that exceeds the capabilities of conventional tools and delivers greater speed and accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005134/en/
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. (Photo: Business Wire)
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. Prüftechnik Adaptive Alignment systems, such as the ShaftAlign Touch, automatically eliminate user errors and low-quality measurement points by adapting to the asset, the alignment situation, and the technician who is performing the job. Cloud-compatible software allows newer technicians to share measurements with more experienced colleagues or consultants — inside the plant or across the globe — to complete a job.
“ShaftAlign Touch is a significant improvement over conventional shaft alignment measurement equipment and basic laser systems in the market,” said Ankush Malhotra, vice president and general manager of Fluke Reliability. “With its intuitive computer-based, guided user interface, single-laser technology, and cloud-transfer capabilities, ShaftAlign Touch, sets a new benchmark for solving alignment issues at an unbeatable price/performance ratio.”
ShaftAlign Touch delivers:
- High performance and precise results — ShaftAlign Touch leverages single-laser technology to provide high-precision, high-performance alignment measurements.
- Quick setup and intuitive user interface — its swift setup and tablet-like, intuitive guided user interface make it more user-friendly than any of the conventional alignment measurement methods.
- Ability to share data via the cloud — technicians can leverage its integrated Wi-Fi cloud solution to easily transfer measurement data from the ShaftAlign Touch handheld device to the ARC 4.0 software.
ShaftAlign Touch is the latest addition to the family of Prüftechnik Adaptive Alignment laser systems. Adaptive Alignment is a combination of software and hardware that enables maintenance and reliability teams to adjust to most any horizontal, angular, or vertical alignment challenge. With Adaptive Alignment solutions, work is completed faster, results are more accurate, and team capabilities are better utilized compared to other market solutions.
For more information on the Prüftechnik ShaftAlign Touch, visit https://www.pruftechnik.com/en-US/Products-and-Services/Alignment-Systems-for-Rotating-Machinery/Shaft-Alignment/Shaft-Alignment-Systems/SHAFTALIGN-touch/.
About Prüftechnik
Prüftechnik is a worldwide provider of maintenance technology with a comprehensive product, service, and training program tailored to the needs of maintenance experts in shaft alignment, vibration analysis, condition monitoring, and destruction-free testing. Many manufacturing companies worldwide trust its solutions for reliable and condition-based maintenance of rotating machines. For more information, visit https://www.pruftechnik.com.
About Fluke Reliability
Fluke Reliability offers reliability and maintenance teams the tools, software, and services they need to optimize asset performance. Home to three powerful iconic brands – Prüftechnik, eMaint, and Fluke Connect – Fluke Reliability serves more than 70,000 customers worldwide with a relentless dedication to quality, innovation, and service. Its products inform customers on the health of their assets, and its software and services drive better maintenance decisions – improving productivity, driving uptime, and reducing costs. For more information, visit https://www.accelix.com.
FLUKE is a registered trademark of Fluke Corporation. For more information, visit the Fluke website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005134/en/
Contact information
Barbara Ellis
(425) 446-4949
barbara.ellis@fluke.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 16:10:00 EET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release
Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom